What is it about?

Chronic Obstructive Pulmonary Disease represents a complex and diverse disease, whose prognosis and response to treatment cannot be adequately predicted by spirometric classification alone. Ongoing research suggests multiple markers of different aspects of disease such as symptoms, severity, progression, exacerbation rate, prognosis, inflammatory status and response to different therapies.

Featured Image

Why is it important?

COPD is a leading cause of morbidity and mortality worldwide. Disease severity evaluation was based on airflow limitation for many years. However, it is now obvious that no single parameter can describe the complexity of COPD and a more holistic approach should be utilised. For this reason, newer classifications of the disease are based on multiple clinical characteristics or biomarkers that can predict different clinically meaningful outcomes, such as symptoms, frequency of exacerbations, progression of disease, response to different medications and mortality. Ongoing research highlights such biomarkers, while guidelines have already incorporated them, as the basis of clinical phenotypes. GOLD highlights the need for more intensive treatment of frequent exacerbators and COPD patients whose disease significantly burdens their quality of life. Moreover, a COPD-asthma overlap syndrome with a different prognosis and potentially different therapeutic approach is also recognised. Spanish guidelines also group frequent exacerbators to predominantly emphysematic versus predominantly bronchitic. Another approach aims to create scoring systems, or multidimensional indices, based on multiple biomarkers which evaluate different aspects of the disease. The recognition of all these prognostic and therapeutic patient subgroups lead to a more personalised approach to each patient and also provides data to the –omics to uncover the pathogenetic background of this diversity and develop new targeted treatments.

Perspectives

Different classification systems, qualitative or quantitative, arise from the combination of different biomarkers representing different aspects of the disease. This, in the short term help us handle COPD patients in a more targeted way and more efficiently, while in the long term feedbacks a great amount of data to the -omics in order to locate the pathophysiological/molecular background of the different subgroups and improve their understanding and management. The real challenge is no longer the need to identify suitable biomarkers or potential phenotypes but to understand their stability over time and value as a guide to treatment. Much work is still to be done if the potential of phenotyping COPD is to be fully realized.

Professor Alexandru Corlateanu
State University of Medicine and Pharmacy "Nicolae Testemitanu"

Read the Original

This page is a summary of: COPD Phenotypes and Biomarkers: Introducing Personalised Medicine, Current Respiratory Medicine Reviews, July 2014, Bentham Science Publishers,
DOI: 10.2174/1573398x10666140527000115.
You can read the full text:

Read

Contributors

The following have contributed to this page